Literature DB >> 17595185

Treatment with recombinant human erythropoietin is associated with rejuvenation of CD8+ T cell compartment in chronic renal failure patients.

Piotr Trzonkowski1, Alicja Debska-Slizien, Andrzej Myśliwski, Bolesław Rutkowski.   

Abstract

BACKGROUND: A growing body of evidence suggests an impact of rHuEpo on the immune system.
METHODS: We assessed the impact of recombinant human erythropoietin (rHuEpo) on the immunity of 11 chronic renal failure patients who did not require haemodialysis. Naïve (Tn), central (Tcm) and effectory memory (Tcm, Tem, TemRA) subsets of CD8+ T cells, memory-CMV-specific CD8+ T cells, titres of anti-CMV antibodies and activity of NK cells were evaluated during the first year of rHuEpo administration.
RESULTS: While the number of CD8 T cells did not change, significant change was found in their proportions. Percentage of Tn cells increased at the expense of Tcm cells. Appearing Tn cells were CD28+ increasing the total pool of CD28+ T cells. Together with decreasing number, Tcm cells changed to mainly CD28- Tcm cells. A 'move' towards the naïve compartment was also confirmed as the level of memory-CMV-specific CD8+ T cells decreased. Humoral immunity analysed as titres of anti-CMV antibodies as well as innate immunity measured as cytotoxicity of NK cells did not change during the follow-up.
CONCLUSIONS: We found that the administration of rHuEpo caused rejuvenation of cellular CD8+ T-dependent immunity in our patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17595185     DOI: 10.1093/ndt/gfm361

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  ESAs in transplant anemia: one size does not "fit all".

Authors:  Anita Mehrotra
Journal:  J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 10.121

2.  Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.

Authors:  Naamit Deshet-Unger; Sahar Hiram-Bab; Yasmin Haim-Ohana; Moshe Mittelman; Yankel Gabet; Drorit Neumann
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

3.  Divide, Conquer, and Sense: CD8+CD28- T Cells in Perspective.

Authors:  Fernando A Arosa; André J Esgalhado; Carolina A Padrão; Elsa M Cardoso
Journal:  Front Immunol       Date:  2017-01-03       Impact factor: 7.561

4.  Erythropoietin enhances Kupffer cell number and activity in the challenged liver.

Authors:  Dafna Gilboa; Yasmin Haim-Ohana; Naamit Deshet-Unger; Nathalie Ben-Califa; Sahar Hiram-Bab; Debby Reuveni; Ehud Zigmond; Max Gassmann; Yankel Gabet; Chen Varol; Drorit Neumann
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

5.  Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine.

Authors:  Magdalena Piotrowska; Maciej Zieliński; Leszek Tylicki; Bogdan Biedunkiewicz; Alicja Kubanek; Zuzanna Ślizień; Karolina Polewska; Piotr Tylicki; Marta Muchlado; Justyna Sakowska; Marcin Renke; Adam Sudoł; Małgorzata Dąbrowska; Monika Lichodziejewska-Niemierko; Tomasz Smiatacz; Alicja Dębska-Ślizień; Piotr Trzonkowski
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.